GLPwatch
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
NCT05611957 · Completed
Last updated 2026-05-28This clinical trial is testing the effects of the drug LY3437943 in both healthy people and those with reduced kidney function to understand how the body processes the medication.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) basic-science study
Participants 29 people
Who can join Ages 18–85 · all sexes Healthy volunteers accepted.
Timeline Started 2022-11 · est. completion 2023-09
Where 4 sites · United States
What this study is testing ClinicalTrials.gov NCT05611957 ↗
Description as written by the study sponsor.
The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 5 weeks, excluding screening.
Treatments tested
- LY3437943 Drug
Administered SC.
| Main thing measured | Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Healthy, Renal Insufficiency |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05611957 ↗